Veena A. Thomas

547 total citations · 1 hit paper
11 papers, 358 citations indexed

About

Veena A. Thomas is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Veena A. Thomas has authored 11 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Veena A. Thomas's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Diabetes Treatment and Management (3 papers) and Protein purification and stability (3 papers). Veena A. Thomas is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Diabetes Treatment and Management (3 papers) and Protein purification and stability (3 papers). Veena A. Thomas collaborates with scholars based in United States, Canada and United Kingdom. Veena A. Thomas's co-authors include Joseph P. Balthasar, Renée Komorowski, Larissa Atangan, Murielle M. Véniant, Shu-Chen Lu, Yuan Cheng, Todd Hager, Shanaka Stanislaus, James R. Falsey and Richard C. Koya and has published in prestigious journals such as Annals of the New York Academy of Sciences, Journal of Pharmacology and Experimental Therapeutics and Pharmacology & Therapeutics.

In The Last Decade

Veena A. Thomas

11 papers receiving 343 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

2024 115 citations Murielle M. Véniant, Shu-Chen Lu et al. Nature Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veena A. Thomas United States	8	163	146	82	70	53	11	358
Wolfgang Glaesner United States	7	210 1.3×	205 1.4×	46 0.6×	30 0.4×	74 1.4×	9	414
Sarah Hamren United States	9	170 1.0×	95 0.7×	20 0.2×	50 0.7×	33 0.6×	10	425
Naim Panjwani Canada	7	198 1.2×	226 1.5×	19 0.2×	45 0.6×	20 0.4×	10	443
Sonali Nayak United States	6	130 0.8×	143 1.0×	15 0.2×	21 0.3×	8 0.2×	10	305
Corinna Schoelch Germany	11	124 0.8×	36 0.2×	13 0.2×	73 1.0×	25 0.5×	20	345
V. Bodart Canada	9	194 1.2×	114 0.8×	11 0.1×	129 1.8×	45 0.8×	9	523
Richard F. Corkey United States	8	185 1.1×	73 0.5×	13 0.2×	118 1.7×	34 0.6×	9	445
Takehiko Takayanagi United States	9	134 0.8×	56 0.4×	27 0.3×	30 0.4×	9 0.2×	12	365
Sandhya Sanghi United States	6	149 0.9×	54 0.4×	48 0.6×	37 0.5×	23 0.4×	8	327
Donny Strosberg France	7	213 1.3×	32 0.2×	10 0.1×	49 0.7×	36 0.7×	8	371

Countries citing papers authored by Veena A. Thomas

Since Specialization

Citations

This map shows the geographic impact of Veena A. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veena A. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veena A. Thomas more than expected).

Fields of papers citing papers by Veena A. Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veena A. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veena A. Thomas. The network helps show where Veena A. Thomas may publish in the future.

Co-authorship network of co-authors of Veena A. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Veena A. Thomas. A scholar is included among the top collaborators of Veena A. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veena A. Thomas. Veena A. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Liu, Clarissa M., Elizabeth A. Killion, Rola Hammoud, et al.. (2025). GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice. Nature Metabolism. 7(6). 1266–1281. 11 indexed citations

Véniant, Murielle M., Shu-Chen Lu, Larissa Atangan, et al.. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism. 6(2). 290–303. 115 indexed citations breakdown →

Li, Peng, Edward L. LaGory, Kevin D. Cook, et al.. (2024). Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo. mAbs. 16(1). 2383013–2383013. 1 indexed citations

Liu, Shufang, Sara C. Humphreys, Kevin D. Cook, et al.. (2023). Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice. mAbs. 15(1). 2263926–2263926. 1 indexed citations

Bakshi, Suruchi, Guy Meno‐Tetang, Aparna Mohan, et al.. (2022). Hallmarks of neurodegenerative disease: A systems pharmacology perspective. CPT Pharmacometrics & Systems Pharmacology. 11(11). 1399–1429. 28 indexed citations

Lu, Shu-Chen, Michelle Chen, Larissa Atangan, et al.. (2021). GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Reports Medicine. 2(5). 100263–100263. 71 indexed citations

Conner, Kip P., et al.. (2020). The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacology & Therapeutics. 212. 107574–107574. 25 indexed citations

Conner, Kip P., et al.. (2020). Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues. mAbs. 12(1). 1746520–1746520. 5 indexed citations

Matsueda, Satoko, et al.. (2019). Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice. Journal of Pharmacology and Experimental Therapeutics. 368(3). 503–513. 34 indexed citations

10.

Thomas, Veena A. & Joseph P. Balthasar. (2019). Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies. 8(4). 56–56. 59 indexed citations

11.

Mollison, Karl W., Thomas A. Fey, R. A. Krause, et al.. (1993). Comparison of FK‐506, Rapamycin, Ascomycin, and Cyclosporine in Mouse Models of Host‐versus‐Graft Disease and Heterotopic Heart Transplantation. Annals of the New York Academy of Sciences. 685(1). 55–57. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact